Increase of sulfated ursodeoxycholic acid in the serum and urine of patients with chronic liver diseases after ursodeoxycholic acid therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 11, Issue 4, 1996, Pages 385-390

  Nakamura, K ^a   Yoneda, M ^a   Kimura, A ^a   Tamori, K ^a   Yokohama, S ^a   Sato, Y ^a   Kato, T ^a   Hasegawa, T ^a   Saito, H ^a   Aoshima, M ^a   Fujita, M ^a   Makino, I ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

bile acid; chronic liver disease; sulfate conjugation; ursodeoxycholic acid; ursodeoxycholic acid therapy

Indexed keywords

BILE ACID; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BILE FLOW; CHRONIC ACTIVE HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG METABOLISM; DRUG SULFATION; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029881283     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1996.tb01388.x     Document Type: Article

References (35)

1. 1 Poupon R., Chétien Y., Poupon RE, Ballet F., Calmus Y., Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis ? Lancet 1987 ; i: 834–6.
2. 2 Leuschner U., Fischer H., Kurtz W. et al. Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double‐blind trial. Gastroenterology 1989 ; 97: 1268–74.
3. 3 Oka H., Toda G., Ikeda Y. et al. A multi‐center double‐blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol. Jpn 1990 ; 25: 774–80.
4. 4 Matsuzaki Y., Tanaka N., Osuga T. et al. Improvement of biliary enzyme levels and itching as a result of long‐term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am. J. Gastroenterol. 1990 ; 85: 15–23.
5. 5 Poupon RE, Balkau B., Eschwege E., Poupon R. The UDCA‐PBC study group: A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N. Engl. J. Med. 1991 ; 324: 1548–54.
6. 6 Poupon RE, Poupon R., Balkau B. The UDCA‐PBC study group: Ursodiol for long‐term treatment of primary biliary cirrhosis. N. Engl. J. Med. 1994 ; 330: 1342–7.
7. 7 Lindor KD, Dickson ER, Baldus WP et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994 ; 106: 1284–90.
8. 8 Heathcote EJ, Cauch‐Dudek K., Walker V. et al. The Canadian multicenter double‐blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994 ; 19: 1149–56.
9. 9 Leuschner U., Güldütuna S., Imhof M., Hübner K., Benjaminov A., Leuschner M. Effect of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. J. Hepatol. 1994 ; 21: 624–33.
10. 10 Leuschner U., Leuschner M., Sieratzki J., Kurtz W., Hübner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years followup. A pilot study. Dig/Dis. Sci. 1985 ; 30: 642–9.
11. 11 Bellentani S., Tabarroni G., Barchi T. et al. Effect of ursodeoxycholic acid treatment on alanine aminotransferase and γ‐glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double‐blind controlled trial. J. Hepatol. 1989 ; 8: 7–12.
12. 12 Osuga T., Tanaka N., Matsuzaki Y., Aikawa T. Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis. Dig. Dis. Sci. 1989 ; 34: S49–51.
13. 13 Podda M., Ghezzi C., Battezzati PM, Crosignani A., Zuin M., Roda A. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Gastroenterology 1990 ; 98: 1044–50.
14. 14 Rolandi E., Franceschini R., Cataldi A., Cicchetti V., Barreca T. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double‐blind controlled study. Eur. J. Clin. Pharmacol. 1991 ; 40: 473–6.
15. 15 Crosignani A., Battezzati PM, Setchell KDR et al. Effect of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: A dose‐response study. Hepatology 1991 ; 13: 339–44.
16. 16 Takano S., Ito Y., Yokosuka O. et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994 ; 20: 558–64.
17. 17 Stiehl A., Rudolph G., Raedsch R. et al. Ursodeoxycholic acid‐induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 1990 ; 12: 492–7.
18. 18 Chrétien Y., Poupon R., Gherardt MF et al. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis. Effect of ursodeoxycholic treatment. Gut 1989 ; 30: 1110–15.
19. 19 Crosignani A., Podda M., Battezzati PM et al. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991 ; 14: 1000–7.
20. 20 Setchell KDR, Watson D., Zimmer‐Nechemias L., Balistreri WF, Yamashita H. Metabolism of ursodeoxycholic acid in normal subjects and in patients with cholestatic liver disease: Biotransformation by conjugation and urinary excretion. Hepatology 1992 ; 16: 120A.
21. 21 Batta AK, Arora R., Salen G., Tint GS, Eskreis D., Katz S. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas‐liquid chromatography‐mass spectrometry: Effect of ursodeoxycholic acid treatment. J. Lipid Res. 1989 ; 30: 1953–62.
22. 22 Makino I., Shinozaki K., Nakagawa, Mashimo K. Measurement of sulfated and nonsulfated bile acids in human serum and urine. J. Lipid Res. 1974 ; 15: 132–8.
23. 23 Palmer RH. The formation of bile acid sulfates: A new pathway of bile acid metabolism in humans. Proc. Natl Acad. Sci. USA 1967 ; 58: 1047–50.
24. 24 O'Brien C., Senior JR, Arora R., Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30 month pilot study. Hepatology 1991 ; 14: 838–47.
25. 25 Beuers U., Spengler U., Kruis W. et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo‐controlled trial. Hepatology 1992 ; 16: 707–14.
26. 26 Loof L., Wengle B. Enzymatic sulfation of bile salts in human liver. Biochim. Biophys. Acta 1978 ; 50: 451–60.
27. 27 Summerfield JA, Gollan JL, Billing BH. Synthesis of bile acid monosulfates by the isolated perfused rat kidney. Biochem. J. 1976 ; 156: 339–45.
28. 28 Dew MJ, Hawker PC, Nutter S. Human intestinal sulfation of lithocholate: A new site for bile acid metabolism. Life Sci. 1980 ; 27: 317–23.
29. 29 Imperato TJ, Chen LJ, Cantor DS, Bolt RJ, Michas CA. Bile salt sulfotransferase activity in human liver. Gastroenterology 1976 ; 71: 912.
30. 30 Marschall H‐U, Egestad B., Matern H. N ‐Acetylglucosa‐minides. A new type of bile acid conjugate in man. J. Biol. Chem. 1989 ; 264: 12 989–93.
31. 31 Marschall H‐U, Matern S., Wiethholtz H., Egestad B., Matern S., Sjövall J. Bile acid N ‐Acetylglucosaminidation. In vivo and in vitro evidence for a selective conjugation reaction of 7β‐hydroxylated bile acids in humans. J. Clin. Invest. 1992 ; 89: 1981–7.
32. 32 Kimura A., Yoneda M., Nakamura K. et al. Urinary bile acid N ‐acetylglucosaminides during ursodeoxycholate (UDCA) treatment in patients with hepatobiliary diseases. Gastroenterology 1994 ; 106: A917.
33. 33 Stiehl A. Bile salt sulphates in cholestasis. Eur. J. Clin. Invest. 1974 ; 4: 59–63.
34. 34 Stiehl A., Earnest D., Admirand WH. Sulfation and renal excretion of bile salts in patients with cirrhosis of the liver. Gastroenterology 1975 ; 68: 534–44.
35. 35 Van Berge Henegouwen GP, Brandt K‐H, Eyssen H., Parmentier G. Sulphated and unsulphated bile acids in serum, bile, and urine of patients with cholestasis. Gut 1976 ; 17: 861–9.